Congruence Therapeutics Starts First-in-Human Trial of MC4R Obesity Drug CGX-926

New updates have been reported about Congruence Therapeutics.

Congruence Therapeutics has initiated first-in-human dosing in its Phase 1/1b trial of CGX-926, positioning the company as a direct player in the emerging market for precision therapies targeting genetic obesity driven by melanocortin-4 receptor (MC4R) mutations. The oral small-molecule corrector is designed to stabilize mutant MC4R, restore receptor folding and trafficking, and re-establish downstream signaling in an estimated 70,000–100,000 affected individuals in the U.S. who currently lack an approved receptor-targeted therapy.

The study, run with Quotient Sciences and led in the Phase 1b portion at the University of Cambridge by obesity genetics expert Dr. Sadaf Farooqi, will assess safety, tolerability, pharmacokinetics, and early efficacy signals, with data expected in the first half of 2027 to inform Congruence’s future development and partnering options. CGX-926, discovered using Congruence’s Revenir computational platform, previously showed dose-dependent weight and food-intake reduction while preserving lean mass in an MC4R-deficient mouse model, reinforcing both the asset’s potential and the value of the company’s broader pipeline strategy across genetic obesity and other protein-misfolding indications.